Active Recombinant Mouse Tgfbr2 Protein (Ile24-Asp184), hFc-tagged

• Cat.No.: Tgfbr2-02M
• Product Overview: Recombinant ouse TGF-beta RII (Ile24 - Asp184) Protein with a Mouse IgG2a (Glu98 - Lys330) Fc tag at C-terminus was expressed in Mouse myeloma cell line.

Specification

• Description: Enables SMAD binding activity; transforming growth factor beta binding activity; and transforming growth factor beta-activated receptor activity. Involved in several processes, including animal organ development; circulatory system development; and positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation. Acts upstream of or within several processes, including animal organ development; cell surface receptor signaling pathway; and positive regulation of tolerance induction. Located in external side of plasma membrane. Is expressed in several structures, including alimentary system; central nervous system; early conceptus; embryo mesenchyme; and genitourinary system. Used to study DiGeorge syndrome; Loeys-Dietz syndrome; cleft soft palate; and prostate cancer. Human ortholog(s) of this gene implicated in Loeys-Dietz syndrome 2; Marfan syndrome; gastrointestinal system cancer (multiple); hereditary nonpolyposis colorectal cancer type 6; and pancreatic cancer. Orthologous to human TGFBR2 (transforming growth factor beta receptor 2).
• Source: Mouse myeloma cell line
• Species: Mouse
• Tag: mFc
• Form: Disulfide-linked homodimer
• Bio-activity: Measured by its ability to inhibit TGF-beta 1 activity on HT-2 mouse T cells. The ED50 for this effect is 3-10 ng/mL in the presence of 1 ng/mL of rhTGF-beta 1.
• Molecular Mass: Predicted Molecular Mass: 45.2 kDa (monomer)
  SDS-PAGE: 66 kDa, reducing conditions
• Protein length: Ile24-Asp184
• N-terminal Sequence Analysis: Ile24
• Endotoxin: <0.01 EU/μg of the protein by the LAL method.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 centigrade as supplied.
  1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
  3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
• Storage Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Reconstitution: Reconstitute at 100 μg/mL in sterile PBS.
• Shipping: The product is shipped at ambient temperature.

Gene Information

• Gene Name: Tgfbr2 transforming growth factor, beta receptor II [ Mus musculus (house mouse) ]
• Official Symbol: Tgfbr2
• Synonyms: Tgfbr2; transforming growth factor, beta receptor II; DNIIR; RIIDN; TBR-II; TbetaRII; TbetaR-II; 1110020H15Rik; TGF-beta receptor type-2; TGF-beta receptor II; TGF-beta receptor type II; TGF-beta type II receptor; TGFR-2; transforming growth factor-beta receptor type II; EC 2.7.11.30
• Gene ID: 21813
• mRNA Refseq: NM_009371
• Protein Refseq: NP_033397
• UniProt ID: Q62312

Reviews

04/14/2023

TGFBR2 protein's remarkable performance in ELISA and protein electron microscopy structure analysis positions it as a valuable tool in various fields, including cardiovascular research, developmental biology, and molecular medicine.

12/13/2022

TGFBR2 protein's utility extends to protein electron microscopy structure analysis, where it plays a crucial role in investigating the detailed architecture and conformational changes of proteins.

06/25/2021

TGFBR2 protein is highly recommended for use in various research applications, including ELISA and protein electron microscopy structure analysis.

Q&As

How is TGFBR2 linked to autoimmune diseases?

Dysregulation of TGF-beta signaling, including TGFBR2, has been associated with autoimmune diseases. Understanding these pathways may provide insights into developing targeted therapies.

Are there clinical trials targeting TGFBR2?

Yes, there are ongoing clinical trials exploring the modulation of TGFBR2 for various conditions, including cancer and fibrotic diseases.

How does TGFBR2 affect cardiovascular health?

TGFBR2 is involved in cardiovascular development and homeostasis. Dysregulation can contribute to conditions like aortic aneurysms and other cardiovascular diseases.

Is TGFBR2 involved in neurological disorders?

Some studies suggest a potential link between TGFBR2 and neurological disorders. Further research is ongoing to understand its role in conditions like Alzheimer's and Parkinson's disease.

Can TGFBR2 be a therapeutic target for fibrotic diseases?

Yes, TGFBR2 is implicated in fibrosis, and targeting it may offer therapeutic options for diseases characterized by excessive tissue scarring.